Gilead’s REMS Resubmission Delays FDA Action On Truvada For PrEP
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA extends the user fee deadline for the supplemental indication of HIV pre-exposure prophylaxis to Sept. 14. Although Gilead is not saying what changes it made to the Risk Evaluation and Mitigation Strategy, FDA advisory committee members had recommended making prescriber education mandatory and linking prescribing to documentation of a negative HIV test.
You may also be interested in...
Two Indications, One REMS: FDA Panel Debates Restricted Access For Truvada In PrEP
FDA did not ask its Antiviral Drugs Advisory Committee whether Gilead’s proposed REMS for pre-exposure prophylaxis should include restricted distribution, but it still got an earful on the subject from some vocal panel members, who said prescribing should be limited only to individuals with documentation of a negative HIV test. Agency staff, however, said such an approach was impractical due to Truvada’s unrestricted availability for HIV treatment.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.